ALLO
Allogene Therapeutics Inc
NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY
$2.13
+0.95% today
Updated 2026-04-30
Market cap
$725.79M
P/E ratio
—
P/S ratio
7,784.36x
EPS (TTM)
$-0.87
Dividend yield
—
52W range
$1 – $4
Volume
10.3M
Allogene Therapeutics Inc (ALLO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-44.65M | $-44.65M | $-137.35M | $-115.09M | $-184.81M | $-220.52M | $-237.73M | $-200.30M | $-149.25M |
| Capital expenditures | $5.33M | $3.23M | $50.79M | $65.96M | $21.45M | $5.19M | $1.52M | $694000.00 | $386000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $18.57M | $46.06M | $65.26M | $80.82M | $83.60M | $65.95M | $51.74M | $37.64M |
| Free cash flow | $-49.98M | $-47.89M | $-188.14M | $-181.05M | $-206.26M | $-225.71M | $-239.25M | $-200.99M | $-149.63M |
| Investing cash flow | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | $93.73M | $85.69M | $13.38M | $-9.19M | — | — | — | — |